Health Trials

About this trial

The goal of this clinical trial is to learn whether platelet-rich plasma (PRP) injection, made from a participant's own blood, can help heal the tendon and improve shoulder symptoms in people with partial tears of the supraspinatus tendon.

The main questions it aims to answer are:

* Does PRP help the tendon heal? * Does PRP improve pain, shoulder movement, daily function, and shoulder magnetic resonance imaging (MRI) findings?

Researchers will compare PRP plus standard of care (physical therapy) to standard of care alone to see if PRP leads to better healing and better clinical results. Researchers will also study if differences in specific biomolecules in PRP are associated with differences in treatment response.

Participants will:

* receive standard of care treatment, with or without PRP injection depending on the study group * have blood collected for PRP preparation * have their pain, shoulder movement, and shoulder function assessed * undergo shoulder MRI scans * be followed over time to measure healing and symptom improvement

Eligibility criteria

Qualifiers

Eligible patients are at least 18 years old, and have clinical (VAS pain score ≥4, loss of >25% in ROM, positive in at least one clinical test such as Jobe, Neer, Drop arm, Hawins-Kennedy, Patte) and imaging findings compatible with partial supraspinatus tear, within 3 months of diagnosis.

Patients may have undergone conservative treatments, including lifestyle modification, oral analgesics, or physical therapy, with the exception of shoulder injections.

Must be willing to provide consent.

Disqualifiers

Patients less than 18 years old

Patients with other or concomitant rotator cuff or shoulder muscle/tendon tear(s), complete tears, SLAP tears ≥ grade 2

Patients with auto-immune based joint diseases, osteoarthritis (KL grade ≥ 2), adhesive capsulitis, infection, nerve-related conditions, immunocompromised conditions, malignancy, coagulopathy

Patients on antiplatelet, anticoagulant, antitumor or immunosuppressive drugs

Trial design

Treatments tested in this trial

  • Platelet-Rich Plasma (PRP) Injections

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Universidade Nova de Lisboa

Lead sponsor

Hospital da Luz, Portugal

Collaborator

Source ClinicalTrials.gov